1 Day
Source:
The Fiscal Times
Source: The Fiscal Times
1 DayThe Fiscal Times
Source: The Fiscal Times
1 DayReady to play
Ready to play
Moderna's shares more than doubled after announcing positive initial results from a study of an experimental mRNA-based cancer vaccine, intismeran, developed with Merck. The vaccine, tailored to individual tumor mutations and paired with Merck’s Keytruda, showed patients experienced longer periods without cancer recurrence compared to those receiving only Keytruda in melanoma cases. The companies plan to present full results at an upcoming international medical conference.
Notice: This Is an AI-Generated Summary
Comments (0)